SI2470168T1 - Postopki za preprečevanje in zdravljenje možganske ishemije - Google Patents

Postopki za preprečevanje in zdravljenje možganske ishemije Download PDF

Info

Publication number
SI2470168T1
SI2470168T1 SI201031644T SI201031644T SI2470168T1 SI 2470168 T1 SI2470168 T1 SI 2470168T1 SI 201031644 T SI201031644 T SI 201031644T SI 201031644 T SI201031644 T SI 201031644T SI 2470168 T1 SI2470168 T1 SI 2470168T1
Authority
SI
Slovenia
Prior art keywords
composition
tocotrienolquinone
alpha
treatment
stereoisomer
Prior art date
Application number
SI201031644T
Other languages
English (en)
Inventor
Guy M. Miller
Viktoria Kheifets
Original Assignee
Bioelectron Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Technology Corporation filed Critical Bioelectron Technology Corporation
Publication of SI2470168T1 publication Critical patent/SI2470168T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

  1. POSTOPKI ZA PREPREČEVANJE IN ZDRAVLJENJE MOŽGANSKE ISHEMIJE EP 2 470 168 B1 PATENTNI ZAHTEVKI
    1. Sestavek za uporabo pri zdravljenju, preprečevanju in/ali izboljšanju nevronske poškodbe, povezane z možganskim ishemičnim dogodkom ali hipoksijo pri sesalcu, ki potrebuje takšno zdravljenje, pri čemer omenjeni sestavek vsebuje učinkovito količino tokotrienol kinona, izbranega iz skupine, ki jo sestavljajo alfa-tokotrienol-kinon, beta-tokotrienol-kinon, gama-tokotrienol-kinon in delta-tokotrienol-kinon ali njihove mešanice ali ena sama stereoizomera ali mešanica njihovih stereoizomer; s pridržkom, da navedeni osebek ne trpi zaradi mitohondrijske bolezni.
  2. 2. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, kjer sestavek obsega učinkovito količino alfa-tokotrienol-kinona ali katerekoli stereoizomere ali mešanice stereoizomer.
  3. 3. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, kjer je cerebralni ishemični dogodek sekundaren za okluzijo cerebralne vaskulature.
  4. 4. Sestavek po zahtevku 3, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je okluzija posledica tromboembolije.
  5. 5. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je cerebralna ishemija posledica krčev koronarne vaskulature.
  6. 6. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer je cerebralni ishemični dogodek sekundaren za prenehanje srčne funkcije, kardiopulmonalni obvodni postopek ali hemoragični dogodek v cerebralni vaskularni bolezni.
  7. 7. Sestavek po zahtevku 2, za uporabo, kot je definiran v omenjenem zahtevku, kjer omenjeni tokotrienol kinonski sestavek obsega vsaj okoli 65% alfa-tokotrienol-kvinona.
  8. 8. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek dodatno obsega farmacevtsko sprejemljiv nosilec.
  9. 9. Sestavek po zahtevku 1 za uporabo, kot je definiran v omenjenem zahtevku, pri čemer se navedeni sestavek daje peroralno.
  10. 10. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, pri čemer se navedeni sestavek daje parenteralno.
  11. 11. Sestavek po zahtevku 2 za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek vsebuje alfa-tokotrienol kinon v količini od okoli 1 do okoli 1000 mg na kg telesne mase omenjenega sesalca.
  12. 12. Sestavek po zahtevku 2, za uporabo, kot je definiran v omenjenem zahtevku, kjer navedeni sestavek vsebuje alfa-tokotrienol kinon v količini od okoli 1 do okoli 50 mg na kg telesne mase omenjenega sesalca.
  13. 13. Sestavek po zahtevku 1, za uporabo, kot je definiran v omenjenem zahtevku, kjer je omenjena nevronska poškodba izbrana izmed smrti nevronske celice, celotnega volumna možganskega infarkta, možganske ishemične poškodbe, edemov možganskega tkiva in kognitivne disfunkcije.
  14. 14. Sestavek za uporabo pri zdravljenju in/ali izboljšanju cerebralnega ishemičnega dogodka ali hipoksije pri sesalcu, ki potrebuje takšno zdravljenje, pri čemer navedeni sestavek vsebuje učinkovito količino tokotrienol-kinona, izbranega iz skupine, ki jo sestavljajo alfa-tokotrienol-kinon, beta -tokotrienol-kinon, gama-tokotrienol-kinon in delta-tokotrienol-kinon ali njihove mešanice, ali ena sama stereoizomera ali mešanica njihovih stereoizomer; s pridržkom, da navedeni osebek ne trpi zaradi mitohondrijske bolezni, pri kateri je možganska kap eden od simptomov mitohondrijske bolezni.
  15. 15. Sestavek po zahtevku 14 za uporabo, kot je definiran v omenjenem zahtevku, kjer sestavek vsebuje učinkovito količino alfa-tokotrienol-kvinona ali katerekoli stereoizomere ali mešanice stereoizomer.
  16. 16. Sestavek po kateremkoli od zahtevkov 1-15, za uporabo, kot je definiran v omenjenem zahtevku, kjer je alfa-tokotrienol kinon ali stereoizomer ali zmesi njegovih stereoizomerov edina aktivna sestavina, prisotna v učinkoviti količini v sestavku.
SI201031644T 2009-08-26 2010-08-24 Postopki za preprečevanje in zdravljenje možganske ishemije SI2470168T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia
EP10747777.0A EP2470168B1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
SI2470168T1 true SI2470168T1 (sl) 2018-05-31

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031644T SI2470168T1 (sl) 2009-08-26 2010-08-24 Postopki za preprečevanje in zdravljenje možganske ishemije

Country Status (17)

Country Link
US (3) US20110207828A1 (sl)
EP (1) EP2470168B1 (sl)
JP (2) JP5785546B2 (sl)
CN (1) CN102647981B (sl)
AU (1) AU2010286704B2 (sl)
BR (1) BR112012004167A2 (sl)
CA (1) CA2772294C (sl)
DK (1) DK2470168T3 (sl)
EA (1) EA028677B1 (sl)
ES (1) ES2663709T3 (sl)
HU (1) HUE037592T2 (sl)
MX (1) MX337990B (sl)
NO (1) NO2470168T3 (sl)
PL (1) PL2470168T3 (sl)
PT (1) PT2470168T (sl)
SI (1) SI2470168T1 (sl)
WO (1) WO2011025785A1 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
ES2714900T3 (es) * 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
DK2362875T3 (en) 2008-10-28 2015-11-30 Edison Pharmaceuticals Inc METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
MY183449A (en) * 2010-04-27 2021-02-18 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
US9162957B2 (en) 2011-07-19 2015-10-20 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
RU2639483C2 (ru) * 2012-03-19 2017-12-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
US9629815B2 (en) 2012-09-07 2017-04-25 Bioelectron Technology Corporation Benzoquinone derivatives for treating oxidative stress disorders
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CN109154603A (zh) 2016-03-16 2019-01-04 奇达拉治疗公司 用于治疗真菌感染的给药方案
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP2020529973A (ja) 2017-07-12 2020-10-15 シダラ セラピューティクス インコーポレーテッド 真菌感染症の処置のための組成物及び方法
WO2020010180A1 (en) * 2018-07-03 2020-01-09 Cardio Vascular Bio Therapeutics, Inc. Compositions and methods for treating stroke
CN113365616A (zh) 2018-10-17 2021-09-07 Ptc医疗公司 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
EP4045526A4 (en) * 2019-10-17 2023-11-15 The Penn State Research Foundation REGENERATION OF FUNCTIONAL NEURONS FOR THE TREATMENT OF HEMORRHAGIC STROKE
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
AU746369B2 (en) 1997-11-17 2002-04-18 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
AU2002327517B2 (en) * 2001-08-21 2008-04-17 Johnson & Johnson Consumer Companies, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ES2714900T3 (es) * 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
EP3456707B1 (en) * 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2710253A1 (en) * 2008-01-07 2009-07-16 Centocor Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US20110046156A1 (en) * 2008-03-05 2011-02-24 Miller Guy M Treatment of hearing and balance impairments with redox-active therapeutics
JP5710277B2 (ja) * 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) * 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
US8314153B2 (en) * 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) * 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
DK2362875T3 (en) * 2008-10-28 2015-11-30 Edison Pharmaceuticals Inc METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES
US20100273892A1 (en) * 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
WO2010126910A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
HUE037574T2 (hu) * 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
MY183449A (en) * 2010-04-27 2021-02-18 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) * 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Also Published As

Publication number Publication date
AU2010286704B2 (en) 2016-10-20
US20180344667A1 (en) 2018-12-06
MX2012002374A (es) 2012-04-10
EA201200355A1 (ru) 2012-07-30
EP2470168A1 (en) 2012-07-04
CN102647981B (zh) 2016-09-28
PT2470168T (pt) 2018-03-28
JP5785546B2 (ja) 2015-09-30
US20170007553A1 (en) 2017-01-12
EA028677B1 (ru) 2017-12-29
JP2013503168A (ja) 2013-01-31
BR112012004167A2 (pt) 2016-03-29
MX337990B (es) 2016-03-30
WO2011025785A1 (en) 2011-03-03
JP2015091899A (ja) 2015-05-14
NO2470168T3 (sl) 2018-06-30
AU2010286704A1 (en) 2012-03-22
DK2470168T3 (en) 2018-05-07
HUE037592T2 (hu) 2018-09-28
PL2470168T3 (pl) 2018-06-29
ES2663709T3 (es) 2018-04-16
CA2772294A1 (en) 2011-03-03
US20110207828A1 (en) 2011-08-25
EP2470168B1 (en) 2018-01-31
CA2772294C (en) 2018-08-21
CN102647981A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
SI2470168T1 (sl) Postopki za preprečevanje in zdravljenje možganske ishemije
JP2013503168A5 (sl)
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
US20170360798A1 (en) Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
MY156858A (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BRPI0511967B8 (pt) derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
MX2010007375A (es) Nuevos derivados de lupano.
GT200000184A (es) Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean.
US20080171709A1 (en) Pharmaceutical Composition Comprising An Antiviral Agent, An Antitumoral Agent Or An Antiparasitic Agent, And An Active Agent Selected Among Carveol, Thymol, Eugenol, Borneol,And Carvacrol
JP2014526541A5 (sl)
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
JP2016521717A (ja) ５環性トリテルペンとヒドロキシチロソール及びその誘導体との組み合わせ
CA2876703A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
EP2857017A2 (en) Use of dimiracetam in the treatment of chronic pain
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2012064159A3 (ko) 항암용 조성물
CN100357312C (zh) 赖氨酸七叶皂苷及其制备方法和其用途
FI3302451T3 (fi) Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa
WO2011122899A3 (ko) 혈소판 응집억제용 또는 혈전용해용 의약 조성물
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof